Hemolytic Anemia

• EMA withdrawal · 2026-08-21
  EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG

  The EMA suspended Oxbryta (voxelotor) for treating sickle cell disease-related anemia.

• EMA withdrawal · 2024-10-08
  EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG

  The EMA has suspended the EU marketing authorization for Oxbryta (voxelotor) by Pfizer Europe MA EEIG, affecting its use for sickle cell dis…

• CLINICAL_TRIALS withdrawal · 2017-10-10
  Clinical Trial Update: The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders [Phase 4]

  Phase 4 trial evaluating ursodeoxycholic acid for treating gallstones in patients with hemolytic disorders was terminated.